PDCD1 and glioma: Furthermore, a preclinical study has confirmed the usefulness of an anti-PD-1 antibody at augmenting DC vaccination in glioma-bearing mice, showing a significant improvement in survival attributed to the strong T cell response enabled by ICI treatment [129].